Teva receives CRL for reformulated schizophrenia drug developed with French biotech

Teva and its partners at the French biotech MedinCell received a complete response letter for their subcutaneous schizophrenia treatment, the companies announced Tuesday afternoon. The pair did not provide a reason as to why regulators issued the CRL, but MedinCell noted in a statement that Teva would be responsible for resolving any concerns.